Search

Your search keyword '"Garcia-Vargas J"' showing total 130 results

Search Constraints

Start Over You searched for: Author "Garcia-Vargas J" Remove constraint Author: "Garcia-Vargas J"
130 results on '"Garcia-Vargas J"'

Search Results

1. Final safety and efficacy results of copanlisib monotherapy in patients with relapsed or refractory iNHL: 6‐year follow‐up of CHRONOS‐1

3. Efficacy and safety of copanlisib in patients with relapsed or refractory marginal zone lymphoma

6. Long-term safety and efficacy of the PI3K inhibitor copanlisib in patients with relapsed or refractory indolent lymphoma: 2-year follow-up of the CHRONOS-1 study

8. Alpha Emitter Radium-223 and Survival in Metastatic Prostate Cancer

9. 260P A phase I study of copanlisib, a pan-class I phosphatidylinositol 3-kinase (PI3K) inhibitor, in Chinese patients with relapsed indolent non-Hodgkin lymphoma (iNHL)

16. Influence des impuretés issues de la combustion du biodiesel sur les propriétés d’adsorption des catalyseurs d’oxydation: étude par DRIFT

17. SAFETY ANALYSIS OF PATIENTS WITH A MEDICAL HISTORY OF RESPIRATORY DISORDERS TREATED WITH COPANLISIB FROM THE CHRONOS-1 STUDY IN RELAPSED OR REFRACTORY INDOLENT B-CELL LYMPHOMA

19. EFFICACY AND SAFETY IN HIGH-RISK RELAPSED OR REFRACTORY INDOLENT FOLLICULAR LYMPHOMA PATIENTS TREATED WITH COPANLISIB

20. Preparación de catalizadores Diesel NOx Trap por via coloidal

21. Phosphatidylinositol 3-kinase inhibition by Copanlisib in relapsed or refractory indolent lymphoma

22. Highly active and stable Ru/K-OMS-2 for NO oxidation

23. Pd/Rh catalysts for the abatement of car emissions pollutants

24. Fe zeolite supported catalysts for the SCR-NH3 reaction

25. Influence du procédé de préparation et de support utilisé sur l'activité de catalyseurs du Fe-zéolites pour la NH3-SCR de NOx

27. Copanlisib treatment in patients with relapsed or refractory indolent B-cell lymphoma: Subgroup analyses from the CHRONOS-1 study

29. COPANLISIB IN PATIENTS WITH RELAPSED OR REFRACTORY INDOLENT B-CELL LYMPHOMA (CHRONOS-1)

30. Influence of the preparation method on the activity of Fe/ZMS-5 catalysts for the SCR of NOx with NH3

31. Re-treatment of Radium-223 From an International, Multicenter, Prospective, Single-Arm Trial in Patients With Castration-Resistant Prostate Cancer and Bone Metastases

32. Radium-223 re-treatment from an international, prospective, open-label study in patients with castration-resistant prostate cancer and bone metastases

33. External-beam radiation therapy (EBRT) use and safety with Radium-223 dichloride (Ra) in patients (pts) with castration-resistant prostate cancer (CRPC) and symptomatic bone metastases (mets) from the ALSYMPCA trial

36. EXTERNAL-BEAM RADIATION THERAPY (EBRT) USE AND SAFETY WITH RADIUM-223 DICHLORIDE (RA) IN PATIENTS (PTS) WITH CASTRATION-RESISTANT PROSTATE CANCER (CRPC) AND SYMPTOMATIC BONE METASTASES (METS) FROM THE ALSYMPCATRIAL

43. Hematologic safety of radium-223 dichloride (Ra-223) in the phase 3 ALSYMPCA trial in castration-resistant prostate cancer (CRPC) patients with bone metastases : baseline prognostic factor subgroup analysis

44. Overall survival benefit and impact on skeletal-related events for radium-223 chloride (Alpharadin) in the treatment of castration-resistant prostate cancer (CRPC) patients with bone metastases : A phase III randomized trial (ALSYMPCA)

49. 130 Overall survival benefit and impact on skeletal-related events for radium-223 chloride (Alpharadin) in the treatment of castration-resistant prostate cancer (CRPC) patients with bone metastases: A phase III randomized trial (ALSYMPCA)

50. Overall Survival Benefit of Radium-223 Chloride (Alpharadin™) in the Treatment of Patients with Symptomatic Bone Metastases in Castration-resistant Prostate Cancer (CRPC): a Phase III Randomized Trial (ALSYMPCA)

Catalog

Books, media, physical & digital resources